Bally M - Search Results

1

Gold-Protein Composite Nanoparticles for Enhanced X-ray Interactions: A Potential Formulation for Triggered Release.

van Ballegooie C, Man A, Pallaoro A, Bally M, Gates BD, Yapp DT. van Ballegooie C, et al. Among authors: bally m. Pharmaceutics. 2021 Sep 4;13(9):1407. doi: 10.3390/pharmaceutics13091407. Pharmaceutics. 2021. PMID: 34575482 Free PMC article.

2

PEG Conjugated Zein Nanoparticles for In Vivo Use.

van Ballegooie C, Wretham N, Ren T, Popescu IM, Yapp DT, Bally MB. van Ballegooie C, et al. Among authors: bally mb. Pharmaceutics. 2022 Aug 31;14(9):1831. doi: 10.3390/pharmaceutics14091831. Pharmaceutics. 2022. PMID: 36145579 Free PMC article.

3

Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin.

Gilabert-Oriol R, Sutherland BW, Anantha M, Pallaoro A, Bally MB. Gilabert-Oriol R, et al. Among authors: bally mb. Drug Deliv Transl Res. 2019 Dec;9(6):1082-1094. doi: 10.1007/s13346-019-00651-0. Drug Deliv Transl Res. 2019. PMID: 31209826

4

Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.

Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, Bally MB. Ho EA, et al. Among authors: bally mb. J Pharm Sci. 2010 Jun;99(6):2839-53. doi: 10.1002/jps.22043. J Pharm Sci. 2010. PMID: 20091826

5

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Verreault M, et al. Among authors: bally mb. BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124. BMC Cancer. 2011. PMID: 21477311 Free PMC article.

6

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Waterhouse DN, et al. Among authors: bally mb. Nanomedicine (Lond). 2011 Nov;6(9):1645-54. doi: 10.2217/nnm.11.140. Nanomedicine (Lond). 2011. PMID: 22077466

7

Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.

Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT. Neijzen R, et al. Among authors: bally mb. J Control Release. 2015 Feb 10;199:72-83. doi: 10.1016/j.jconrel.2014.11.031. Epub 2014 Dec 8. J Control Release. 2015. PMID: 25497312

8

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB. Verreault M, et al. Among authors: bally mb. J Control Release. 2012 Feb 28;158(1):34-43. doi: 10.1016/j.jconrel.2011.09.095. Epub 2011 Oct 5. J Control Release. 2012. PMID: 22001870

9

Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM. Chittaranjan S, et al. Among authors: bally mb. Clin Cancer Res. 2014 Jun 15;20(12):3159-73. doi: 10.1158/1078-0432.CCR-13-2060. Epub 2014 Apr 10. Clin Cancer Res. 2014. PMID: 24721646

10

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB. Verreault M, et al. Among authors: bally mb. J Control Release. 2015 Dec 28;220(Pt A):348-357. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1. J Control Release. 2015. PMID: 26528901

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

354 results

Search Page